Open AccessP1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
Author(s) -
Reiter A.,
Gotlib J.,
ÁlvarezTwose I.,
Radia D. H.,
Luebke J.,
Bobbili P. J.,
Wang A.,
Norregaard C.,
Dimitrijević S.,
Sullivan E.,
LouieGao M.,
Schwaab J.,
Galinsky I. A.,
Perkins C.,
Sperr W. R.,
Sriskandarajah P.,
Chin A.,
Sendhil S. R.,
Duh M. S.,
Valent P.,
DeAngelo D. J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846928.64504.71
Subject(s) - tryptase , medicine , discontinuation , confounding , proportional hazards model , systemic mastocytosis , immunology , mast cell , disease